*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter - as a primary diagnosis code | T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter - as a primary or secondary diagnosis code | |
|---|---|---|
| OUTCOMES | ||
| Avg. LOS | 5.32 | |
| Readmission Rate (%) | 20.13 | |
| Unplanned Readmission Rate (%) | NA | |
| Mortality Rate (%) | ||
| SNF Discharge Rate (%) | ||
| Home Discharge Rate (%) | ||
| PAYMENTS AND CHARGES | ||
| Total Medicare Payments | ||
| Payment Per Day | ||
| Payment Per Hospitalization | ||
| Total Medicare Charges | ||
| Avg. Charges | ||
| MARKET SIZING & INCIDENCE RATES | ||
| Total National Projected Hospitalizations - Annualized (Present on Admission - All) | ||
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - All) | ||
| Total National Projected Hospitalizations - Annualized (Present on Admission - Yes) | ||
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - Yes) | ||
| Total National Projected Hospitalizations - Annualized (Present on Admission - Not Y) | ||
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - Not Y) | ||
| Total Medicare Hospitalizations after Exclusion | ||
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 683: RENAL FAILURE WITH COMPLICATION OR COMORBIDITY (CC) | DRG 916: ALLERGIC REACTIONS WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 291: HEART FAILURE AND SHOCK WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 682: RENAL FAILURE WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 641: MISCELLANEOUS DISORDERS OF NUTRITION, METABOLISM , FLUIDS AND ELECTROLYTES WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 434,264 | ||||
| Total Hospitalizations with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | 601 | ||||
| DRG Share of Total Hospitalizations | 1.32 | ||||
| % of Total ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter in DRG | 11.34 | ||||
| Avg LOS at DRG | 3.94 | ||||
| Avg LOS with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | 3.74 | ||||
| Readmission Rate at DRG | 22.76 | ||||
| Readmission Rate with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | 17.24 | ||||
| Unplanned Readmission Rate at DRG | 16.46 | ||||
| Unplanned Readmission Rate with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | 12.8 | ||||
| Total Medicare payments at DRG | $2,472,138,198 | ||||
| Total Medicare payments with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | $3,216,338 | ||||
| Total Medicare payment per Day at DRG | $1,444 | ||||
| Total Medicare payment per Day with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | $1,432 | ||||
| Total Medicare payment per Hospitalization at DRG | $5,693 | ||||
| Total Medicare payment per Hospitalization with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | $5,352 | ||||
| Total Medicare Charges at DRG | $12,478,361,060 | ||||
| Total Medicare Charges with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | $16,760,851 | ||||
| Avg Charges at DRG | $28,735 | ||||
| Avg Charges with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | $27,888 | ||||
| Mortality Rate at DRG | 0.91 | ||||
| Mortality Rate with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | NA | ||||
| SNF Discharge Rate at DRG | 22.02 | ||||
| SNF Discharge Rate with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | 16.47 | ||||
| Home Discharge Rate at DRG | 46.68 | ||||
| Home Discharge Rate with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | 57.24 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 871: SEPTICEMIA OR SEVERE SEPSIS WITHOUT MV >96 HOURS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 915: ALLERGIC REACTIONS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 684: RENAL FAILURE WITHOUT COMPLICATION OR COMORBIDITY (CC)/MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 312: SYNCOPE AND COLLAPSE | DRG 292: HEART FAILURE AND SHOCK WITH COMPLICATION OR COMORBIDITY (CC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 1,808,415 | ||||
| Total Hospitalizations with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | 166 | ||||
| DRG Share of Total Hospitalizations | 5.5 | ||||
| % of Total ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter in DRG | 3.13 | ||||
| Avg LOS at DRG | 6.34 | ||||
| Avg LOS with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | 7.06 | ||||
| Readmission Rate at DRG | 24.2 | ||||
| Readmission Rate with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | 23.45 | ||||
| Unplanned Readmission Rate at DRG | 16.78 | ||||
| Unplanned Readmission Rate with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | 20.0 | ||||
| Total Medicare payments at DRG | $21,288,214,047 | ||||
| Total Medicare payments with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | $1,961,324 | ||||
| Total Medicare payment per Day at DRG | $1,857 | ||||
| Total Medicare payment per Day with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | $1,673 | ||||
| Total Medicare payment per Hospitalization at DRG | $11,772 | ||||
| Total Medicare payment per Hospitalization with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | $11,815 | ||||
| Total Medicare Charges at DRG | $107,155,481,388 | ||||
| Total Medicare Charges with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | $10,516,738 | ||||
| Avg Charges at DRG | $59,254 | ||||
| Avg Charges with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | $63,354 | ||||
| Mortality Rate at DRG | 12.11 | ||||
| Mortality Rate with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | 7.83 | ||||
| SNF Discharge Rate at DRG | 27.18 | ||||
| SNF Discharge Rate with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | 26.51 | ||||
| Home Discharge Rate at DRG | 25.81 | ||||
| Home Discharge Rate with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | 32.53 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 189: PULMONARY EDEMA AND RESPIRATORY FAILURE | DRG 190: CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 309: CARDIAC ARRHYTHMIA AND CONDUCTION DISORDERS WITH COMPLICATION OR COMORBIDITY (CC) | DRG 280: ACUTE MYOCARDIAL INFARCTION, DISCHARGED ALIVE WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 470: MAJOR JOINT REPLACEMENT OR REATTACHMENT OF LOWER EXTREMITY WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 539,642 | ||||
| Total Hospitalizations with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | 85 | ||||
| DRG Share of Total Hospitalizations | 1.64 | ||||
| % of Total ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter in DRG | 1.6 | ||||
| Avg LOS at DRG | 6.42 | ||||
| Avg LOS with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | 5.92 | ||||
| Readmission Rate at DRG | 26.55 | ||||
| Readmission Rate with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | 25.93 | ||||
| Unplanned Readmission Rate at DRG | 20.01 | ||||
| Unplanned Readmission Rate with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | 17.28 | ||||
| Total Medicare payments at DRG | $5,267,842,463 | ||||
| Total Medicare payments with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | $691,826 | ||||
| Total Medicare payment per Day at DRG | $1,520 | ||||
| Total Medicare payment per Day with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | $1,375 | ||||
| Total Medicare payment per Hospitalization at DRG | $9,762 | ||||
| Total Medicare payment per Hospitalization with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | $8,139 | ||||
| Total Medicare Charges at DRG | $25,503,568,329 | ||||
| Total Medicare Charges with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | $3,859,692 | ||||
| Avg Charges at DRG | $47,260 | ||||
| Avg Charges with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | $45,408 | ||||
| Mortality Rate at DRG | 5.62 | ||||
| Mortality Rate with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | NA | ||||
| SNF Discharge Rate at DRG | 19.26 | ||||
| SNF Discharge Rate with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | 16.47 | ||||
| Home Discharge Rate at DRG | 39.65 | ||||
| Home Discharge Rate with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | 41.18 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 191: CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH COMPLICATION OR COMORBIDITY (CC) | DRG 208: RESPIRATORY SYSTEM DIAGNOSIS W VENTILATOR SUPPORT <=96 HOURS | DRG 308: CARDIAC ARRHYTHMIA AND CONDUCTION DISORDERS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 287: CIRCULATORY DISORDERS EXCEPT AMI, WITH CARDIAC CATETERIZATION WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 193: SIMPLE PNEUMONIA AND PLEURISY WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 286,456 | ||||
| Total Hospitalizations with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | 64 | ||||
| DRG Share of Total Hospitalizations | 0.87 | ||||
| % of Total ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter in DRG | 1.21 | ||||
| Avg LOS at DRG | 3.75 | ||||
| Avg LOS with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | 4.83 | ||||
| Readmission Rate at DRG | 22.9 | ||||
| Readmission Rate with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | 24.59 | ||||
| Unplanned Readmission Rate at DRG | 18.29 | ||||
| Unplanned Readmission Rate with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | 22.95 | ||||
| Total Medicare payments at DRG | $1,641,467,496 | ||||
| Total Medicare payments with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | $381,369 | ||||
| Total Medicare payment per Day at DRG | $1,526 | ||||
| Total Medicare payment per Day with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | $1,234 | ||||
| Total Medicare payment per Hospitalization at DRG | $5,730 | ||||
| Total Medicare payment per Hospitalization with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | $5,959 | ||||
| Total Medicare Charges at DRG | $8,050,963,680 | ||||
| Total Medicare Charges with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | $2,187,868 | ||||
| Avg Charges at DRG | $28,105 | ||||
| Avg Charges with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | $34,185 | ||||
| Mortality Rate at DRG | 0.24 | ||||
| Mortality Rate with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | NA | ||||
| SNF Discharge Rate at DRG | 10.84 | ||||
| SNF Discharge Rate with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | NA | ||||
| Home Discharge Rate at DRG | 59.73 | ||||
| Home Discharge Rate with ICD T445X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter | 53.13 |
| Hospital Name | Address | City | State | Zip Code | Total Hospitalizations ( Oct 2015 to Sep 2018 ) |
|---|---|---|---|---|---|
| CHRISTIANA CARE WILMINGTON HOSPITAL | 501 W 14TH ST | WILMINGTON | DE | 19801 | 56 |
| REGIONAL MEDICAL CENTER | 400 E 10TH ST | ANNISTON | AL | 36207 | 33 |
| AURORA ST. LUKE'S MEDICAL CENTER | 2900 W OKLAHOMA AVE | MILWAUKEE | WI | 53215 | 24 |
| Physician Name | Address | City | State | Zip Code | Total Hospitalizations ( Oct 2015 to Sep 2018 ) |
|---|---|---|---|---|---|
| Dr. ZIAD SOUS | 1145 S UTICA AVE | TULSA | OK | 74104 | 13 |